ClinicalTrials.gg
CompletedNCT01200108Updated Nov 15, 2011

AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects With Asthma

A Phase 2 interventional study of Budesonide and Budesonide in Asthma, sponsored by Activaero GmbH. Completed at 24 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-11-15.

Sponsored by Activaero GmbH · Phase 2 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Started
2010
with 5 others
Phase 2
5 of 110
none open now
Registered
68th of 110
by date

Among the 110 studies testing budesonide in Asthma, this one is one of 6 that started in 2010, is one of 5 in phase 2, and was the 68th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The goal of treatment with AICS is weaning from oral corticosteroids, i.e. a reduction of the oral corticosteroid dose. An anticipated treatment benefit of AICS is a reduction of oral corticosteroid dose and stability/improvement of clinical parameters related to asthma in the targeted subject population. Ultimately, the goal is to free subjects with severe asthma from the burden of chronic oral steroid therapy.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Severe Asthma, requiring chronic oral steroid use
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written prior to the performance of any study-related procedures
  • Age ≥ 18 and ≤ 65 year of age Diagnosis of asthma (ATS definition, either allergic or non-allergic) for ≥ 6 months
  • Asthma treated for at least 3 months with inhaled (ICS) and oral (OCS). Exact baseline level will be measured during the screening period by subject diary entries
  • ≥ 40% or ≤ 79% predicted at the Screening or Baseline Visit
  • Documented increase of FEV1 within 15-30 minutes after the use of inhaled Salbutamol at the Screening Visit or within 2 years prior to Screening
  • Mandatory usage of long-acting β-agonists
  • A negative pregnancy test must be available for any women of at screening and, in addition, a negative urine pregnancy test must be present at randomization (prior to randomization to one of the treatment groups!)
  • Women of childbearing potential must agree to use a reliable method of from the screening until 4 weeks after study completion or after study drug discontinuation in case study drug treatment is stopped prematurely. - In this study, hormone-based contraceptives alone are not considered as reliable method

Exclusion criteria

Exclusion Criteria:

  • History of allergy or adverse experience with Budesonide
  • Pregnant women or nursing mothers
  • Upper respiratory tract infection within 4 weeks of Screening
  • Emergency room visit for treatment of asthma exacerbation within 4 weeks of Screening
  • Hospitalization for asthma within 3 months of Screening
  • Use of anti-IgE, methotrexate, oral gold, Dapsone, or i.v. gamma globulin within 3 months of Screening
  • Treatment with other asthma treatment within 30 days prior to Screening
  • Evidence of chronic lung diseases other than asthma, including but not limited to: cystic fibrosis, allergic bronchopulmonary aspergillosis (ABPA), , chronic bronchitis and emphysema
  • History of medication noncompliance
  • History of significant medical illness or condition that in the Investigator's opinion places the subject at undue risk by participating in the study
  • Past episode of anaphylaxis with severe respiratory symptoms
  • Oral average daily dose exceeding a maximum amount
  • Currently smoking or history of smoking ≥ 10 pack years
  • Taking oral or i.v. corticosteroids for any disease indication other than asthma
  • Abnormal lab values for chemistry tests at Screening that may indicate impaired ability to metabolize and/or excrete Budesonide (, ALT > 3 times , serum creatinine > 1.5 times upper limit of normal range)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2

Study arms

  • Experimental
    Budesonide high dose via AKITA (1mg/2ml)

    Drug: Budesonide

  • Experimental
    Budesonide low dose via AKITA (0.5mg/2ml)

    Drug: Budesonide

  • Active comparator
    Budesonide high dose via conventional nebulizer (1mg/2ml)

    Drug: Budesonide

  • No intervention
    Placebo via AKITA

Interventions

06

Study locations

24 sites
  • Berlin, 10717, Germany
  • Bonn, 53119, Germany
  • Bonn, 53123, Germany
  • Darmstadt, 64287, Germany
  • Peter, Kardos, MD
    Frankfurt, 60318, Germany
  • Marburg, 35037, Germany
  • München, 80331, Germany
  • Rodgau-Dudenhofen, 63110, Germany
  • Rüdersdorf, 15562, Germany
  • Schwetzingen, 68723, Germany
  • Katowice, 40-752, Poland
  • Kraków, 31-159, Poland
  • Lublin, 20-954, Poland
  • Lódz, 92-215, Poland
  • Poznán, 60-214, Poland
  • Skierniewice, 96-100, Poland
  • Warszawa, 02-097, Poland
  • Wroclaw, 50-239, Poland
  • Dnipropetrovsk, 49074, Ukraine
  • Donetsk, 83099, Ukraine
  • Ivano-Frankivsk, 76018, Ukraine
  • Kharkiv, 61124, Ukraine
  • Kyiv, 03680, Ukraine
  • Vinnytsia, 21029, Ukraine
07

References and documents

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Oct 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2010
First posted
Sep 13, 2010
Start
Mar 2010
Primary completionActual
Oct 2011
CompletionActual
Nov 2011
Last update
Nov 15, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01200108
Lead sponsor
Activaero GmbH
First posted
Sep 13, 2010
Start date
Mar 2010
Primary completion
Oct 2011
Completion
Nov 2011
Last update
Nov 15, 2011

Study contacts

Peter Kardos, MD
principal investigator · Peter Kardos

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion